摘要
目的:探讨门诊抑郁症患者抗抑郁药治疗现状及相关因素分析。方法:全国多中心调查1503例抑郁症患者一般资料,并指导患者进行相关量表评定;比较抗抑郁药单药治疗组(单药组)和抗抑郁药联合治疗组(联合组)的一般资料,分析抗抑郁药联合治疗的相关因素。结果:1503例抑郁症患者中,单药组1219例(81.1%),联合组284例(18.9%);最为常见的联合用药组合为文拉法辛和米氮平、艾司西酞普兰和米氮平。Logistic回归分析显示,就诊医院类型(OR=2.73)、是否共病躯体疾病(OR=1.66)、患者健康问卷躯体症状群量表(PHQ-15)得分(OR=0.55)与急性期是否换药(OR=2.09)是抗抑郁药联合治疗的相关因素(P均<0.01)。结论:就诊于综合医院、伴躯体疾病、PHQ-15<6分、急性期更换抗抑郁药是门诊抑郁症患者采用抗抑郁药联合治疗的因素。
Objective:To explore the current status of antidepressant treatment and correlative factors in outpatients with depression.Method:There were 1503 patients included in this study from multiple centers in China.We collected their general and medical information,and guided patients to evaluate relevant scales.We compared the differences of general information between antidepressant monotherapy group(M-group)and antidepressant co-treatment group(C-group),and analyzed the correlative factors of antidepressant co-treatment.Results:There were 1219 cases(81.1%)in M-group and 284 cases(18.9%)in C-group among the 1503 patients with depression.The most common combinations were venlafaxine with mirtazapine,and escitalopram with mirtazapine in this study.Logistic regression analysis suggested that the type of hospital(OR=2.73),with comorbid physical diseases(OR=1.66),the score of PHQ-15(OR=0.55)and changing antidepressant in the acute stage(OR=2.09)were related factors of antidepressant co-treatment(all P<0.01).Conclusion:Visiting the general hospitals,with comorbid physical diseases,the score of PHQ-15<6,and changing antidepressant in the acute stage are related factors of antidepressant co-treatment.
作者
刘珊珊
朱雪泉
丰雷
冯媛
房萌
肖乐
LIU Shan-shan;ZHU Xue-quan;FENG Lei;FENG Yuan;FANG Meng;XIAO Le(National Clinical Research Center for Mental Disorders,Beijing Anding Hospital,Capital Medical University,Beijing 100088,China)
出处
《临床精神医学杂志》
CAS
2022年第2期85-89,共5页
Journal of Clinical Psychiatry
基金
国家重点研发计划(2017YFC1311101)
北京市医院管理中心“青苗”计划专项经费资助(QML20181902,QML20181905)。
关键词
抑郁症
抗抑郁药
联合治疗
相关因素
depression
antidepressant
co-treatment
correlative factors
